Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/270
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joshua, Douglas E. | en |
dc.contributor.author | Penny, Ron | en |
dc.contributor.author | Matthews, Jane P. | en |
dc.contributor.author | Laidlaw, Christine R. | en |
dc.contributor.author | Gibson, John | en |
dc.contributor.author | Bradstock, Ken | en |
dc.contributor.author | Wolf, Max | en |
dc.contributor.author | Goldsien, David | en |
dc.date.accessioned | 2013-05-29T03:27:40Z | en |
dc.date.available | 2013-05-29T03:27:40Z | en |
dc.date.issued | 1997 | en |
dc.identifier.govdoc | 00260 | en |
dc.identifier.issn | 0007-1048 | en |
dc.identifier.uri | http://hdl.handle.net/11054/270 | en |
dc.description.abstract | The Australian Leukaemia Study Group has performed a randomized trial of interferon α-2A (Roferon-A) as a co-induction agent together with intensive combination chemotherapy and as maintenance following completion of 12 cycles of induction treatment. When used as a co-induction agent, interferon-α did not improve response rates, time-to-treatment failure, or overall survival. Patients who had interferon together with intensive combination therapy (PCAB: prednisone 60 mg/m2 days 1–5, cyclophosphamide 600 mg/m2 day 1, BCNU 30 mg/m2 day 1, doxorubicin 30 mg/m2 day 1, repeated every 28 d for a total of 12 cycles) had more leucocyte and granulocyte toxicity and received a lower dose intensive of cytotoxic drugs than those patients who received PCAB without interferon. There was a trend towards prolongation of plateau phase which did not reach significance. Interferon, however, did improve the survival of patients who achieved plateau; for those patients interferon was associated with a 33% decrease in the rate of death after adjusting for initial beta-2 microglobulin level. This trial was undertaken with assistance from Ballarat Base Hospital - Dr R. Bell. | en |
dc.description.provenance | Submitted by Gemma Siemensma (gemmas@bhs.org.au) on 2013-05-22T05:33:01Z No. of bitstreams: 0 | en |
dc.description.provenance | Approved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2013-05-29T03:27:40Z (GMT) No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2013-05-29T03:27:40Z (GMT). No. of bitstreams: 0 Previous issue date: 1997 | en |
dc.publisher | Wiley | en |
dc.relation.uri | http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.1997.9942643.x/abstract | en |
dc.title | Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. | en |
dc.type | Journal Article | en |
dc.type.specified | Article | en |
dc.bibliographicCitation.title | British Journal of Haematology | en |
dc.bibliographicCitation.volume | 97 | en |
dc.bibliographicCitation.issue | 1 | en |
dc.bibliographicCitation.stpage | 38 | en |
dc.bibliographicCitation.endpage | 45 | en |
dc.publisher.place | London, UK | en |
dc.subject.healththesaurus | LEUKAEMIA | en |
dc.subject.healththesaurus | CANCER | en |
dc.subject.healththesaurus | CHEMOTHERAPY | en |
dc.subject.healththesaurus | MYELOMA | en |
dc.subject.healththesaurus | RANDOMIZED CONTROL TRIAL | en |
dc.subject.healththesaurus | ONCOLOGY | en |
dc.subject.healththesaurus | INTERFERON | en |
dc.subject.healththesaurus | CO-INDUCTION THERAPY | en |
dc.subject.healththesaurus | PLATEAU | en |
dc.subject.healththesaurus | SURVIVAL RATE | en |
dc.date.issuedbrowse | 1997-01-01 | en |
Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.